Achillion Pharmaceuticals, Inc.  

(Public, NASDAQ:ACHN)   Watch this stock  
Find more results for ACHN
6.91
+0.08 (1.17%)
After Hours: 6.90 -0.01 (-0.14%)
Jul 23, 7:44PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.84 - 7.12
52 week 2.26 - 8.61
Open 6.92
Vol / Avg. 2.66M/10.49M
Mkt cap 668.86M
P/E     -
Div/yield     -
EPS -0.65
Shares 96.80M
Beta 2.04
Inst. own 102%
Aug 4, 2014
Q2 2014 Achillion Pharmaceuticals Inc. Earnings Release (Estimated) Add to calendar
Jun 24, 2014
Achillion Pharmaceuticals Inc at JMP Securities Healthcare Conference
Jun 18, 2014
Achillion Pharmaceuticals Inc at Wells Fargo Healthcare Conference
Jun 3, 2014
Achillion Pharmaceuticals Inc. 2014 Annual Shareholder Meeting
May 19, 2014
Achillion Pharmaceuticals Inc. at UBS Global Healthcare Conference
May 14, 2014
Achillion Pharmaceuticals Inc. at Bank of America Merrill Lynch Health Care Conference
May 7, 2014
Achillion Pharmaceuticals Inc. at Deutsche Bank Healthcare Conference
May 7, 2014
Q1 2014 Achillion Pharmaceuticals Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -41.58% -48.33%
Return on average equity -44.29% -52.40%
Employees 61 -
CDP Score - -

Address

300 George Street
NEW HAVEN, CT 06511
United States - Map
+1-203-6247000 (Phone)
+1-203-6247003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.

Officers and directors

David I. Scheer Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Milind S. Deshpande Ph.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Mary Kay Kay Fenton CPA Chief Financial Officer, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Gautam Shah Ph.D. Executive Vice President, Chief Compliance Officer
Age: 57
Bio & Compensation  - Reuters
David Apelian M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Joseph Truitt Senior Vice President, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Michael D. Kishbauch Director
Age: 65
Bio & Compensation  - Reuters
Jason S. Fisherman M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Gary E. Frashier Independent Director
Age: 75
Bio & Compensation  - Reuters
Kurt C. Graves Independent Director
Age: 46
Bio & Compensation  - Reuters